Axsome's depression drug enters competitive market after U.S. approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Axsome's depression drug enters competitive market after U.S. approval

Axsome Therapeutics (AXSM) Rallies After Auvelity Gains FDA Approval

August 19, 2022 2:13 PM EDT

Biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) surged Friday after it announced that the U.S. Food and Drug Administration (FDA) has approved Auvelity for treating major depressive disorder (MDD) in adults.

Axsome shares hit a high of $61.11 following the news. They have since... More

Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval

August 19, 2022 10:39 AM EDT

Cowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.

The analyst... More